



- (51) **International Patent Classification:**
A01K 67/027 (2006.01)
- (21) **International Application Number:**
PCT/US2019/023899
- (22) **International Filing Date:**
25 March 2019 (25.03.2019)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/648,197 26 March 2018 (26.03.2018) US
62/689,628 25 June 2018 (25.06.2018) US
- (71) **Applicant: REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591-6706 (US).
- (72) **Inventors: VORONINA, Vera;** c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **MOMONT, Corey;** c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **MCWHIRTER, John;** c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **TU, Naxin;** c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **MACDONALD, Lynn;** c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **MURPHY, Andrew J.;** c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).
- (74) **Agent: JONES, Brendan T. et al.;** Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,


(54) **Title:** HUMANIZED RODENTS FOR TESTING THERAPEUTIC AGENTS

Figure 1A

(57) **Abstract:** Provided herein are methods and compositions related to the *in vivo* testing of therapeutic agents comprising a human Fc in genetically modified rodents (*e.g.*, the testing of the pharmacokinetic and/or pharmacodynamic properties of such a therapeutic agent in genetically modified rodents). In some embodiments the genetically modified rodents express antibodies comprising a human Fc (*e.g.*, a human IgG1 Fc, a human IgG4 Fc). In some embodiments, the rodents express fully human antibodies (*i.e.*, antibodies having human heavy chains and human light (γ or κ) chains). In certain embodiments the genetically modified rodents comprise one or more Fc receptors with a human extracellular domain (*e.g.*, a Neonatal Fc Receptor (FcRn), a β -2-microglobulin polypeptide (β 2M), a Fc ϵ receptor 1 α (Fc ϵ R1 α), a Fc γ receptor 1 alpha (Fc γ R1 α), a Fc gamma receptor 2a (Fc γ R2a), a Fc gamma receptor 2b (Fc γ R2b), a Fc gamma receptor 3a (Fc γ R3a), a Fc gamma receptor 3b (Fc γ R3b), a Fc gamma receptor 2c (Fc γ R2c)). The transmembrane and

[Continued on next page]

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*